$CDR-PB

CEDAR REALTY TRUST, INC. (CDR-PB): Results of Operations and Financial Condition

CEDAR REALTY TRUST, INC. (CDR-PB) filed an SEC Form 8-K — Results of Operations and Financial Condition. cdr-20260806 0000761648 FALSE 0000761648 2026-08-06 2026-08-06 0000761648 us-gaap:SeriesBPreferredStockMember 2026-08-06 2026-08-06 0000761648 us-gaap:SeriesCPreferredStockMember 2026-08-06 2026-08-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-

Original reporting
Published Aug 6, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CDR-PB
Neutral
low confidence
Mentioned
$CDR-PB
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDR-PBNeutralLow
01

Why it matters

Traders should treat this as a prompt to pull Exhibits 99.1 and 99.2 for the actual financial metrics and any commentary that could affect preferred credit risk and distribution expectations.

02

Market read

The excerpt confirms the filing and the existence of supplemental financial information, but does not provide the figures needed to judge credit or earnings impact.

03

What to watch

Preferred-series trading can hinge on coverage, leverage, and any changes in distribution expectations, which are not included in the scraped excerpt.

Relevance 7/10Novelty 2/10Timing: filed after-hours on Aug 6, 2026

Background

The filing is an SEC Form 8-K for Cedar Realty Trust, Inc., referencing results of operations and financial condition and incorporating information from Wheeler Real Estate Investment Trust’s related disclosures.

Company-level read

Ticker impact

$CDR-PBNeutralLow confidence
Context

Cedar Realty Trust filed an 8-K with Item 2.02 results of operations and financial condition for its preferred stock series.

Expected impact

Limited immediate trading impact from the provided text alone; impact depends on the missing Exhibit 99.1 and 99.2 financial details.

Evidence & confidence

The body confirms the existence of supplemental financial information for the three and six months ended June 30, 2026, but provides no numbers, outlook, or qualitative drivers.

Market effects

REIT preferreds may see mild read-through if the missing exhibits show credit or occupancy stress, but no such details are present here.

No region-specific operational details are included in the scraped text.

No global macro or cross-border implications are disclosed in the provided content.

Counterpoint

If Exhibit 99.1/99.2 contain strong operating trends or improved liquidity, the preferred could re-rate, but that cannot be inferred from the scraped text.

Key entities

  • Cedar Realty Trust, Inc.

    Registrant filing the 8-K for results of operations and financial condition.

  • Wheeler Real Estate Investment Trust, Inc. (WHLR)

    Parent company that made available supplemental financial information and a press release on Aug 6, 2026.

Related articles

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.

$TAPMed

Molson Coors Beverage Company Q2 2026 Earnings Call Summary

Molson Coors reported Q2 2026 volume pressure tied to an energy and inflation shock after conflict in Iran, plus stronger promotions and geopolitical uncertainty in EMEA and APAC. The company reaffirmed FY2026 guidance, citing improving U.S. industry volumes, 1% to 2% annual U.S. price increases, and Midwest Premium aluminum COGS above $130 million, partly hedged. It also outlined a $450 million cost-savings plan and Atomic Brands integration.

$ITTMed

ITT Inc. Q2 2026 Earnings Call Summary

ITT Inc. reported Q2 2026 results driven by 13% organic revenue growth, including 17% at CCT and 21% at Flow Technologies. Full-year organic revenue guidance was raised to 5% to 8% and margin expansion of over 100 bps is expected. Management cited SPX FLOW integration synergies, $71m one-time acquisition costs, and Middle East order delays.